Atlas FDA

REVANESSE ULTRA

FDA premarket approval P160042 · decided 2017-08-04

Approval details

PMA number
P160042
Trade name
REVANESSE ULTRA
Generic name
Implant, dermal, for aesthetic use
Applicant
Prollenium Medical Technologies, Inc.
Date received
2016-09-22
Decision date
2017-08-04
Days to decision
316 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Aurora
Statement
Approval for the Revanesse Ultra. The device is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.